Clinical trials: Non-invasive
Prostate Cancer
Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)
Study design: -The study will be a phase I like study to assess the extent to which prostate HistoScanning (PHS, the index test) can identify and characterize foci of prostate cancer when compared to histological samples…
- Trial name
- PHS-02 (NCT01191931)
- Where
- 7 sites in Belgium, Czechia and 3 more
- Volunteers
- 52 people
- Sponsor
- Advanced Medical Diagnostics s.a.
Temporomandibular Joint Disorders, TMD
Efficacy and Safety of HA35 Gel Nighttime Occlusive Application for TMD Pain
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of nighttime occlusive application of 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with temporomandibular…
- Conditions
- Temporomandibular Joint Disorders, TMD, Temporomandibular Joint Pain, Jaw Muscle Over-Tension
- Trial name
- HA35-TMJ (NCT07584642)
- Testing
- 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Gel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nakhia Impex LLC
Neoplasms, Neutropenia
PC001- A Study to Evaluate the Usability of PointCheck
This a study about the usability of PointCheck a novel non-invasive technology for monitoring chemotherapy-induced neutropenia. The study will include patients with cancer visiting the outpatient hematology clinic for their…
- Trial name
- NCT04448301
- Testing
- PointCheck
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Leuko Labs, Inc.
Chronic Obstructive Pulmonary Disease
HomeVent ( Connect) Registry: EU COPD Home NIV Registry
The prevalence of chronic respiratory disease, including chronic obstructive pulmonary disease (COPD), is increasing in industrialized countries.
- Trial name
- HOmeVent (NCT02811588)
- Testing
- Non-invasive ventilation
- Where
- 4 sites in Germany
- Volunteers
- 169 people
- Sponsor
- ResMed
Aneuploidy, Trisomy 21
Non-Invasive Chromosomal Evaluation of Trisomy Study
This study is being conducted to provide clinically annotated samples to support continued improvements in the Ariosa Test content, methodology, specimen processing and quality control.
- Conditions
- Aneuploidy, Trisomy 21, Trisomy 18, Trisomy 13
- Trial name
- NICHE (NCT02201862)
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Cindy Cisneros
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
- Trial name
- SunRISe-2 (NCT04658862)
- Testing
- Cetrelimab, TAR-200, Cisplatin
- Where
- 290 sites in United States, Argentina and 23 more
- Volunteers
- 518 people
- Sponsor
- Janssen Research & Development, LLC
Nocturnal Hypoventilation, Neuromuscular Disease
Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Newly Diagnosed Patients
The aim of the study is to compare the efficacy and tolerance of autotitrating non-invasive ventilation (NIV) versus standard NIV in patients with newly diagnosed nocturnal hypoventilation who have never experienced nocturnal…
- Conditions
- Nocturnal Hypoventilation, Neuromuscular Disease, Chest Wall Disorder
- Trial name
- NCT00901485
- Testing
- AutoVPAP, VPAPIIIST-A
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- ResMed
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer
A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT
This is a Phase 3, open-label, randomized trial designed to evaluate the DFS of TURBT followed by NDV-1 (sustained-release gemcitabine-docetaxel) versus TURBT followed by surveillance for the treatment of participants with…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer, Urothelial Carcinoma Bladder, Urologic Cancer
- Trial name
- BOOST (NCT07313891)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Sponsor
- Relmada Therapeutics, Inc.
Non-muscle Invasive Bladder Cancer
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer.
- Trial name
- CREST (NCT04165317)
- Testing
- PF-06801591, Bacillus Calmette-Guerin
- Where
- 196 sites in United States, Australia and 12 more
- Volunteers
- 1,068 people
- Sponsor
- Pfizer
Non-muscle Invasive Bladder Cancer
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab.
- Trial name
- NCT07206225
- Testing
- PF-08052667, Sasanlimab, BCG
- Where
- 68 sites in United States, France and 4 more
- Volunteers
- 294 people
- Sponsor
- Pfizer
Non-muscle Invasive Bladder Cancer
Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
To evaluate the clinical efficacy (median event-free survival) of APL-1202 in combination with Epirubicin hydrochloride versus Epirubicin hydrochloride alone in intermediate and high-risk chemo-refractory non-muscle invasive…
- Trial name
- ACCRUE (NCT04490993)
- Testing
- APL-1202 in combination with Epirubicin
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
This is a phase Ib, open-label, single-arm, single-center study conducted in Canada. Subjects with NMIBC (Ta, T1, and/or Tis) who are not candidates for or have refused radical cystectomy will be eligible for participation in the…
- Trial name
- NCT03053635
- Testing
- TLD1433 infusion and photodynamic therapy (PDT) treatment
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Theralase® Technologies Inc.
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
This Phase 3, single-arm, multicenter study was designed to evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with recurrent low-grade intermediate-risk…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- UTOPIA (NCT06331299)
- Testing
- UGN-103
- Where
- 48 sites in United States, Bulgaria and 5 more
- Volunteers
- 99 people
- Sponsor
- UroGen Pharma Ltd.
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Expansion of SCG/GCG-Based CAD Sceering: Inclusion of Healthy Controls and CCTA Patients
This study evaluates a new, non-invasive method for screening coronary artery disease (CAD) using seismocardiography (SCG) and gyrocardiography (GCG).
- Trial name
- HF-CAD-CCTA (NCT06880133)
- Testing
- Seismocardiography (SCG) and Gyrocardiography (GCG) Screening
- Where
- Uzbekistan
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Heart Force Medical Inc.
Diabetes
A Study of Stress Heart Imaging in Patients With Diabetes at Risk for Coronary Disease.
The study is designed to see if stress heart imaging can be used as a screening exam in patients with diabetes and risk factors of developing of coronary artery disease and experiencing future cardiac events.
- Trial name
- NCT00162344
- Testing
- Technetium Tc99m Sestamibi
- Where
- 12 sites in United States, Canada
- Volunteers
- 205 people
- Sponsor
- Lantheus Medical Imaging
Diagnosis of Cancer of Various Organs
Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types
ClearNote Health is developing a test from whole blood for the early detection of multiple cancers. The goal of this study is to employ genomics, epigenomics and proteomics methodology for the detection of cancer signal in the…
- Trial name
- NCT03869814
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- ClearNote Health
Non-invasive Lipolysis
Histological Study to Assess Safety and Efficacy of the TempSure Firm for Non-Invasive Lipolysis
This is a prospective, open-labeled, non-randomized, multi-center clinical study to collect safety and efficacy data on the TempSure Firm.
- Trial name
- NCT04878172
- Testing
- TempSure Firm
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cynosure, Inc.
Patients in ICU
Temple Touch Pro (TTP) Non-Invasive Core Temperature Monitoring as a Measure for Early Detection of Fever Related Infections, Including Sepsis.
The study has 2 phases: The Retrospective Phase (50 patients were diagnosed to have sepsis according to our definition and criteria and 30 patients as a controlled cases ) The Prospective Phase (600 patients who will be admitted…
- Trial name
- TTP (NCT03195439)
- Testing
- TTP
- Where
- Israel
- Volunteers
- 600 people
- Sponsor
- Medisim Ltd
Fat Necrosis, Muscle Stimulation
Safety and Efficacy of Electronic Stimulation for Circumferential Reduction and Muscle Toning
Open-label, baseline-controlled, multi-center study evaluating an electrical muscle stimulation system for circumferential reduction and muscle toning.
- Trial name
- NCT06152900
- Testing
- Accufit
- Where
- 2 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- CynosureLutronic
Non-Muscle Invasive Bladder Neoplasms
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus…
- Trial name
- MoonRISe-3 (NCT06919965)
- Testing
- TAR-210, Mitomycin C, Gemcitabine
- Where
- 114 sites in United States, Argentina and 13 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC